Cytokinetics (CYTK)
(Delayed Data from NSDQ)
$52.63 USD
-0.05 (-0.09%)
Updated Sep 26, 2024 04:00 PM ET
After-Market: $52.33 -0.30 (-0.57%) 5:40 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
Cytokinetics, Incorporated [CYTK]
Reports for Purchase
Showing records 101 - 120 ( 313 total )
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
1Q19 Results; Cardiac Programs in the Spotlight for Now; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
KOLs Offer Important Perspective About Moving Reldesmtiv Forward
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Bad Headline, Impressive Data; Reldesemtiv Effects Consistent; Target Increased to $26
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Data, Drivers, and Decisions; It''s Crunch Time
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
GALACTIC-HF Passes Important Test; Project Visibility on Program to Increase Significantly
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Omecamtiv Consistently Improves Heart Failure Irrespective of Atrial Fibrillation
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
2018 Results; Ready; Set; Go For Major Catalysts This Year; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Multiple Critical Drivers in 2019; the Year of Major Visibility
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Innovation Drives Expected Clinical Pipeline Expansion
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Reldesemtiv Hopefully to Show FORTITUDE; Enrollment Completed
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
3Q18 Results; Programs Continue Expansion With Drive Toward Meaningful Inflection Points
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Couple of Interim Setbacks to Reldesemtiv Program; Omecamtiv Drives Lion''s Share of Valuation; Target Adjusted to $21
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
2Q18 Results; Discussions Revving Up for SMA Next Steps; Bring on the FDA; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
For a Hypothesis Generating Study, We Sure Are Impressed With Reldesemtiv; Target Increased to $24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
1Q18 Results; Flow of Clinical Data Starting in June for Reldesemtiv in SMA
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
2017 Results; Anticipation Mounting for Reldesemtiv Data Readouts
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
The Year of CK-107; That Blood Brain-Barrier Is Our Friend; Target Increased to $20
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Tirasemtiv out as Focus Shifts to CK-107 and Then Omecamtiv Longer Term; Target Reduced to $17
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J